CELC Overview

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Wall Street analysts forecast CELC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is106.50 USD with a low forecast of 94.00 USD and a high forecast of 126.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Celcuity Inc revenue for the last quarter amounts to -49.20M USD, increased 35.06

Celcuity Inc. EPS for the last quarter amounts to -36452000.00 USD, increased 31.05

Celcuity Inc (CELC) has 155 emplpoyees as of May 11 2026.

Today CELC has the market capitalization of 6.34B USD.